NCT04376515 is a NA clinical trial of HOPE intervention in COVID-19 Vaccination, sponsored by University of California, Irvine.

Who is sponsoring NCT04376515?

NCT04376515 is sponsored by University of California, Irvine.

What drugs are being tested in NCT04376515?

Interventions in NCT04376515: HOPE intervention.

What condition does NCT04376515 study?

NCT04376515 studies COVID-19 Vaccination.

Is NCT04376515 still recruiting?

NCT04376515 is currently completed. Last updated 2 May 2025.

Are results published for NCT04376515?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-05-02 · How we verify

NCT04376515

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HOPE Intervention for COVID-19

Completed NA Results posted Last updated 2 May 2025

What this trial tests

NA trial testing HOPE intervention in COVID-19 Vaccination in 120 participants. Completed in 30 September 2021.

Timeline

23 July 2021

Primary endpoint
30 September 2021

30 September 2021

Quick facts

Lead sponsor	University of California, Irvine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	120
Start date	23 July 2021
Primary completion	30 September 2021
Estimated completion	30 September 2021
Sites	1 location across United States

Drugs / interventions tested

HOPE intervention

Conditions studied

COVID-19 Vaccination — all drugs for COVID-19 Vaccination →

Sponsor

University of California, Irvine

Who can join

18 and older, any sex, with COVID-19 Vaccination. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Requests for a COVID-19 Vaccine Resource Sheet Primary · 1 time request during the 4-week study

Whether or not the participant requested that our study team send them an electronic resource sheet on the COVID-19 vaccine and where they can get vaccinated.

Group	Value	95% CI
HOPE Intervention	6
Control	0

Proof of COVID-19 Vaccination Secondary · 1 time proof during 4-week study and up to 2 weeks after

Whether or not a participant sent us a proof of a COVID-19 Vaccination

Group	Value	95% CI
HOPE Intervention	10
Control	6

Sponsor's own description

The Harnessing Online Peer Education COVID-19 (HOPE COVID-19) intervention will assess whether a peer-led online support community can improve behavioral health outcomes related to COVID-19.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

An online community peer support intervention to promote COVID-19 vaccine information among essential workers: a randomized trial.
Ugarte DA, Lin J, Qian T, Young SD. · · 2022 · cited 9× · PMID 36314847 · DOI 10.1080/07853890.2022.2138960

Verify or expand the search:

Other recruiting trials for COVID-19 Vaccination

Currently open trials in the same condition.

NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT06613984 — Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) · active not recruiting
NCT06156254 — Community Care Intervention to Decrease COVID-19 Vaccination Inequities · NA · recruiting
NCT04967807 — Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study) · NA · active not recruiting
NCT04980560 — Gut Microbiota Profile and Its Impact on Immunity Status in COVID-19 Vaccinated Cohorts · active not recruiting

Other University of California, Irvine trials

Trials by the same sponsor.

NCT06952725 — Chatbot for Online Support Groups to Treat Tobacco Addiction · NA · not yet recruiting
NCT07167862 — Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound · Phase 4 · not yet recruiting
NCT07527325 — Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma · Phase 2 · not yet recruiting
NCT07391891 — Musical Mindfulness for Pain in the ED Waiting Room · NA · not yet recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04376515 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Irvine
Last refreshed: 2 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04376515.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing